2022
Exploratory study of the dose-related safety, tolerability, and efficacy of dimethyltryptamine (DMT) in healthy volunteers and major depressive disorder
D’Souza D, Syed SA, Flynn LT, Safi-Aghdam H, Cozzi NV, Ranganathan M. Exploratory study of the dose-related safety, tolerability, and efficacy of dimethyltryptamine (DMT) in healthy volunteers and major depressive disorder. Neuropsychopharmacology 2022, 47: 1854-1862. PMID: 35660802, PMCID: PMC9372173, DOI: 10.1038/s41386-022-01344-y.Peer-Reviewed Original ResearchConceptsMajor depressive disorderHealthy controlsAntidepressant effectsDosing sessionsPsychotomimetic effectsDepressive disorderAbuse liabilityTreatment-resistant major depressive disorderDose-related safetyTreatment-resistant individualsMDD participantsPhase 1 studyHAMD-17 scoresTreatment of depressionFurther rigorous trialsMin of injectionExploratory pilot studyPsychedelic drugsAdverse eventsBlood pressureHAMD-17Cardiovascular functionRigorous trialsHealthy volunteersHeart rate
2019
20 The Need for Speed: Adjunctive Triple Chronotherapy in the Accelerated Treatment of Acute Depression and Suicidality in the Adolescent Population
Hurd D, Arzubi E, Herrera M, Coombs N, Brant J. 20 The Need for Speed: Adjunctive Triple Chronotherapy in the Accelerated Treatment of Acute Depression and Suicidality in the Adolescent Population. CNS Spectrums 2019, 24: 183-184. DOI: 10.1017/s1092852919000142.Peer-Reviewed Original ResearchTriple chronotherapyAcute depressionAdolescent populationSecondary outcomesPilot studySeverity of illnessHAMD-17 scoresBright light therapyAdjunctive treatmentPrimary outcomeAdjunctive interventionSevere depressionLight therapyDepressive symptomsSleep deprivationDepressionAccelerated treatmentSuicidalityInterventionOutcomesTreatmentChronotherapyScoresSignificant improvementAdolescents
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply